Dan Landau
cancer evolution biology
Dan Landau, MD, PhD
New York, NY
United States
Weill Cornell Medicine
Dan Landau, MD, PhD is Associate Professor of Medicine at Weill Cornell Medicine and a Core Member of the New York Genome Center. He is an hemato-oncologist whose long-term goal is to develop novel approaches to address cancer evolution as a central obstacle to cure. His research group is funded by the NCI, NHLBI and NHGRI, and his work has led to recognition and awards including Stand Up to Cancer, Burroughs Wellcome Fund, Vallee Scholar, and the NIH Director’s New Innovator Award.
Program Name(s)
Career Development Program
Project Title
Defining the role of DNA methylation modifier mutations in reshaping blood differentiation topology
Patrizia Mondello
IgM MGUS & Waldenstrom Macroglobulinemia
Patrizia Mondello, MD, PhD
Rochester, MN
United States
Mayo Clinic
I am a physician-scientist focusing on the biology and therapeutic targeting of B-cell lymphoma. I trained in Medical Oncology in Italy. Given my interest in the molecular mechanisms underlying cancer development, I enrolled in a PhD program in Cellular Biology and Experimental Medicine at Memorial Sloan Kettering (MSK). I explored the impact of novel therapeutic agents aimed at disrupting well-defined oncogenic signaling pathways. I pursued postdoctoral studies at Weill Cornell. The focus of my postdoctoral research was aberrant epigenetic programming and development of precision therapies in B-cell lymphoma. I then honed my clinical expertise in lymphoma as an advanced fellow at MSK. I further enhanced my research skills in immunotherapy and epigenetic as an advanced fellow at Mayo Clinic. Most recently, I have started my independent research program at Mayo Clinic focusing on epigenetic dysregulations in B cell malignancies and their impact on the tumor microenvironment.
Program Name(s)
Special Grants
Project Title
Siegfried Janz
Myeloma immunotherapy
Siegfried Janz, MD
Wauwatosa, WI
United States
Medical College of Wisconsin
Siegfried Janz, MD, DSc, Professor and William G. Schuett, Jr., Multiple Myeloma Endowed Chair directs translational myeloma research at the Division of Hematology, Oncology & Bone Marrow Transplantation, Department of Medicine, Medical College of Wisconsin Milwaukee. After obtaining his medical degree and board certification in Clinical Immunology from Leipzig University Medical School, Germany, he received advanced training in genetic and biological pathways of myeloma development at the National Cancer Institute, NIH, Bethesda, Maryland. In 2018 he relocated his laboratory to Milwaukee, where he works in close association with his clinical colleagues to enhance our understanding of the natural history of myeloma and improve myeloma treatment and outcomes. His ongoing efforts concentrate on the design and testing of novel immunotherapies that rely on patient-derived T lymphocytes to seek out and kill myeloma.
Program Name(s)
Translational Research Program
Project Title
Improving outcomes of multiple myeloma using TGF-beta resistant BCMA-targeted CAR T cells
Logan Spector
childhood leukemia epidimiology
Logan Spector, PhD
Minneapolis, MN
United States
University of Minnesota
Dr. Logan Spector is a childhood cancer epidemiologist who studies the etiology of these diseases, with a particular focus on childhood leukemia. He received his Ph.D. from Emory University in 2002 and since then has been faculty at the University of Minnesota, where he started and leads the Childhood Cancer Genomics Group. He is immediate past Chair for Epidemiology with the Children’s Oncology Group and is current Chair of the Childhood Cancer and Leukemia International Consortium. Dr. Spector uses both classic and genetic epidemiology to understand the causes of childhood leukemia with the goals of predicting risk, enabling early detection, and, someday, preventing it entirely.
Program Name(s)
Special Grants
Project Title
Genomics of childhood leukemia: Analysis of diverse, worldwide populations
Lei Ding
myeloproliferative neoplasms, myelofibrosis
Lei Ding, PhD
New York, NY
United States
Columbia University Medical Center
Dr. Ding is the Gurewitsch and Vidda Foundation Associate Professor of Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Department of Microbiology and Immunology at Columbia University Medical Center. His laboratory studies mechanisms, particularly cell extrinsic mechanisms, that regulate blood forming stem cells, and how dysregulation of these mechanisms contributes to blood cancers. Dr. Ding’s research has resulted in better characterization of the bone marrow niche in normal and blood cancer disease conditions and may lead to novel therapies.
Program Name(s)
Career Development Program
Project Title
Targeting the interaction of leukemia stem cells with their niche to treat myelofibrosis
Constellation Pharmaceuticals
myeloproliferative neoplasms
Constellation Pharmaceuticals, INC
Cambridge, MA
United States
TAP Partner
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. MorphoSys, a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for people living with cancer and autoimmune diseases, acquired Constellation and continues to develop pelabresib in multiple clinical studies in patients with myeloproliferative neoplasms.
Program Name(s)
Therapy Acceleration Program
Project Title
Matteo Bellone
Smoldering multiple myeloma
Matteo Bellone, MD
Lombardia,
Italy
Fondazione Centro San Raffaele
Dr. Matteo Bellone obtained an M.D. degree (with honors) and was Board Certified in Allergology and Clinical Immunology at the Università degli Studi di Milano, Italy. He had a 3-year post-doctoral training at the University of Minnesota working on autoimmunity with Bianca Conti-Fine. Since the early nineties he has been investigating interactions between cancer and immune cells with discoveries leading to several clinical outputs. He is Head of the Cellular Immunology Unit at Ospedale San Raffaele (Milan, Italy), where he also practices as Clinical Immunologist. He is adjunct professor of Immunology at Università Vita-Salute San Raffaele, Milan, Associate Editor at Frontiers in Immunology and Frontiers in Oncology, and member of several boards serving scientific journals and charities. He is Secretary and Treasurer of the Network Italiano per la BioTerapia dei Tumori (NIBIT), Council Member of the European Network for Cancer Immunotherapy (ENCI), and member of the SIICA, and the AACR.
Program Name(s)
Translational Research Program
Project Title
Gut microbiota modulation to prevent progression of smoldering multiple myeloma to active disease
Alison Moskowitz
lymphoma therapeutics
Alison Moskowitz, MD
New York, NY
United States
Memorial Sloan Kettering Cancer Center
Dr. Alison Moskowitz is an Associate Attending and Clinical Director of the Lymphoma service at Memorial Sloan Kettering Cancer Center. She earned her medical degree at Albert Einstein College of Medicine, completed an internship and residency in internal medicine at Columbia University Medical Center, and completed fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Dr. Moskowitz’s research is dedicated to developing new treatment strategies for T-cell lymphoma and relapsed/refractory Hodgkin lymphoma. The T-cell lymphomas are rare diseases that are typically associated with poor prognosis. She aims to develop new agents for T-cell lymphoma through clinical trials that incorporate strong correlative studies aimed at identifying markers of sensitivity and resistance. These studies will allow us to design personalized treatment approaches, predict optimal combination strategies, and ultimately improve prognosis by rationally designing regimens that target the diverse T-cell lymphoma entities.
Program Name(s)
Career Development Program
Project Title
JAK/STAT inhibition as a therapeutic strategy in T-cell lymphoma
Bruno Paiva
smoldering myeloma
Bruno Paiva, PhD
Pamplona,
Spain
Universidad de Navarra
Dr Bruno Paiva, PharmD, PhD, is a research fellow of the Departments of Haematology and Immunology at the Clinica Universidad de Navarra and CIMA, Pamplona, Spain. He is also the Director of the Flow Cytometry Core of the University of Navarra. Dr Paiva’s main area of expertise is the multidimensional flow cytometry analysis of haematological malignancies. His research focuses on immunogenomics to improve differential diagnosis, risk stratification, and monitoring of patients with monoclonal gammopathies and myeloid malignancies. He is an author or co-author of hundreds of publications in peer-reviewed journals, and has been recognized with numerous awards.
Program Name(s)
Translational Research Program
Project Title
Systematic multiomic profiling of tumor and immune cells for non invasive detection of early myeloma
Michaela Reagan
Multiple Myeloma
Michaela Reagan, PhD
Scarborough, ME
United States
Maine Medical Center
Dr. Michaela Reagan is a Faculty Scientist II at the MaineHealth Institute for Research and an Associate Professor at Tufts University School of Medicine. She received her B.S. in general Engineering from Harvey Mudd College (2006) and Ph.D. from Tufts University in Biomedical Engineering in the field of breast cancer bone metastasis (2011). She then performed her post-doctoral research at the Dana-Farber Cancer Institute in the laboratory of Dr. Irene Ghobrial (2011-2015). Dr. Reagan is a member of the Finance Committee of the American Society of Bone and Mineral Research (ASBMR) and is the past chair of the ASBMR’s Women’s Committee. Since 2015, she has led innovative, transdisciplinary, basic and translational research in the Reagan Laboratory at MaineHealth with the goal of identifying cancer vulnerabilities that can lead to new treatments or cures for multiple myeloma (MM) patients. Her unique research is focused on the interactions between obesity, adipocytes and myeloma cells.
Program Name(s)
Career Development Program
Project Title
Caron Jacobson
lymphoma and immunotherapy
Caron Jacobson, MD
Boston, MA
United States
Dana-Farber Cancer Institute
I graduated from Columbia College of Physicians & Surgeons, where I stayed for Internal Medicine residency training/chief residency before moving to Boston for fellowship training in hematology/oncology at Dana-Farber/Mass General Cancer Center. I stayed on as faculty in the lymphoma program at Dana-Farber and am now an Assistant Professor of Medicine at Harvard Medical School. My research interests are in the clinical and translational study of immunotherapies for lymphoma, with a particular interest in cellular immunotherapies. I also serve as the Medical Director of the Immune Effector Cell Therapy program at Dana-Farber, which houses our commercial and research cell therapy programs across the Institute. I am the principal investigator of industry-sponsored and investigator-initiated clinical trials involving cellular therapies for lymphoma, and lead retrospective and translational studies to identify mechanisms of response and resistance to these therapies.
Program Name(s)
Career Development Program
Project Title
Jean Koff
Disparities in DLBCL
Jean Koff, MD, MSc
Winship Cancer Institute
Dr. Jean Koff is an Associate Professor in the Department of Hematology and Medical Oncology and Director of the Lymphoma Program’s Translational Research Team at Winship Cancer Institute of Emory University. Her clinical expertise in lymphoma is complemented by her research characterizing the immunologic and genetic factors that contribute to poor outcomes in lymphoma patient populations under-represented in most studies, such as African Americans and organ transplant recipients. She serves as an investigator on several team science projects involving multi-institutional cohorts of lymphoma patients with integrated analyses of clinical and molecular data, including the Lymphoma Epidemiology of Outcomes cohort study. Dr. Koff is the 2024 Chair of the Scientific Committee on Lymphoid Neoplasia for the American Society of Hematology. Her work has been funded by the Lymphoma Research Foundation, the American Association for Cancer Research, the American Cancer Society, and the NIH.
Program Name(s)
Specialized Center of Research Program
Project Title
Translating molecular profiles into treatment approaches to target disparities in lymphoma